

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



May 27, 2025

Company name: Fuso Pharmaceutical Industries, Ltd.
Representative: Mikio Toda, President and Representative Director
(Securities code: 4538, Tokyo Stock Exchange Prime Market)
Inquiries: Corporate Communication Office, Corporate Planning Division
(Telephone (main): +81-6-6969-1131)

Notice Concerning the Conclusion of a Special Overdraft Agreement

Fuso Pharmaceutical Industries, Ltd. (the "Company") resolved to enter into a special overdraft agreement (the "Agreement") with Sumitomo Mitsui Banking Corporation at the Board of Directors meeting held on June 2, 2025. The Company hereby announces the details as follows.

1. Purpose of this Agreement

As announced in the "Notice regarding the Appeal Court Decision in the Patent Infringement Lawsuit Against Us" dated May 27, 2025, the Company has entered into this Agreement in order to secure mid- to long-term liquidity in light of the judgment issued against Toray Industries, Inc. ordering the payment of a total of 7,472,878,838 yen, plus late payment charges thereon. As we have already announced, we find the contents of this ruling to be completely unacceptable as our arguments have been largely ignored, and we are currently preparing to appeal to the Supreme Court.

2. Overview of the Agreement

(1) Contracting Party	Sumitomo Mitsui Banking Corporation
(2) Contract limit	8 billion yen
(3) Contract Interest Rate	Base rate plus spread
(4) Contract signing date	June 2, 2025
(5) Contract Term	June 1, 2026
(6) Presence or absence of collateral	Unsecured

3. Future Outlook

There will be no change to the financial results forecast for the fiscal year ending March 31, 2026 as a result of this transaction.